New Aβ(1–42) ligands from anti-amyloid antibodies: Design, synthesis, and structural interaction

Alzheimer's disease (AD), is the most common neurodegenerative disorder of the aging population resulting in progressive cognitive and functional decline. Accumulation of amyloid plaques around neuronal cells is considered a critical pathogenetic event and, in most cases, a hallmark of the path...

Full description

Saved in:
Bibliographic Details
Published in:European journal of medicinal chemistry 2022-07, Vol.237, p.114400-114400, Article 114400
Main Authors: Santoro, Angelo, Grimaldi, Manuela, Buonocore, Michela, Stillitano, Ilaria, Gloria, Antonio, Santin, Matteo, Bobba, Fabrizio, Sublimi Saponetti, Matilde, Ciaglia, Elena, D'Ursi, Anna Maria
Format: Article
Language:English
Subjects:
Aged
Alzheimer
Alzheimer Disease - metabolism
Amyloid - chemistry
Amyloid beta-Peptides - metabolism
Amyloid plaques
Amyloidosis
Antibody
Aptamers
Biomarkers
Humans
Immunotherapy
Ligands
Peptide design
Peptide Fragments - chemistry
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Alzheimer's disease (AD), is the most common neurodegenerative disorder of the aging population resulting in progressive cognitive and functional decline. Accumulation of amyloid plaques around neuronal cells is considered a critical pathogenetic event and, in most cases, a hallmark of the pathology. In the attempt to identify anti-AD drug candidates, hundreds of molecules targeting Aβ peptides have been screened. Peptide molecules have been widely explored, appreciating chemical stability, biocompatibility, and low production cost. More recently, many anti-Aβ(1–42) monoclonal antibodies have been developed, given the excellent potential of immunotherapy for treating or preventing AD. Antibodies are versatile ligands that bind a large variety of molecules with high affinity and specificity; however, their extensive therapeutic application is complex and requires huge economic investments. Novel approaches to identify alternative antibody formats are considered with great interest. In this context, taking advantage of the favorable peptide properties and the availability of Aβ-antibodies structural data, we followed an innovative research approach to identify short peptide sequences on the model of the binding sites of Aβ(1–42)/antibodies. WAibH and SYSTPGK were designed as mimics of solanezumab and aducanumab, respectively. Circular dichroism and nuclear magnetic resonance analysis reveal that the antibody-derived peptides interact with Aβ(1–42) in the soluble monomeric form. Moreover, AFM microscopy imaging shows that WAibH and SYSTPGK are capable of controlling the Aβ(1–42) aggregation. The strategy to identify WAibH and SYSTPGK is innovative and can be widely applied for new anti-Aβ antibody mimicking peptides. [Display omitted] •Immunotherapy targeting Aβ peptides has excellent potential for treating or preventing Alzheimer's disease (AD).: Several monoclonal antibodies against Aβ(1–42) have been developed, though their production is complex and requires substantial economic investments.•We developed an innovative research approach to design peptide sequences from antibodies targeting different Aβ(1–42)'s epitopes.•CD and NMR based techniques help to probe secondary structure perturbations in Aβ(1–42) in presence of the designed peptides.
ISSN:0223-5234
1768-3254
DOI:10.1016/j.ejmech.2022.114400